» Articles » PMID: 38001629

A Radiomics Approach to Identify Immunologically Active Tumor in Patients with Head and Neck Squamous Cell Carcinomas

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Nov 25
PMID 38001629
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We recently developed a gene-expression-based HOT score to identify the hot/cold phenotype of head and neck squamous cell carcinomas (HNSCCs), which is associated with the response to immunotherapy. Our goal was to determine whether radiomic profiling from computed tomography (CT) scans can distinguish hot and cold HNSCC.

Method: We included 113 patients from The Cancer Genome Atlas (TCGA) and 20 patients from the Groupe Hospitalier Pitié-Salpêtrière (GHPS) with HNSCC, all with available pre-treatment CT scans. The hot/cold phenotype was computed for all patients using the HOT score. The IBEX software (version 4.11.9, accessed on 30 march 2020) was used to extract radiomic features from the delineated tumor region in both datasets, and the intraclass correlation coefficient (ICC) was computed to select robust features. Machine learning classifier models were trained and tested in the TCGA dataset and validated using the area under the receiver operator characteristic curve (AUC) in the GHPS cohort.

Results: A total of 144 radiomic features with an ICC >0.9 was selected. An XGBoost model including these selected features showed the best performance prediction of the hot/cold phenotype with AUC = 0.86 in the GHPS validation dataset.

Conclusions And Relevance: We identified a relevant radiomic model to capture the overall hot/cold phenotype of HNSCC. This non-invasive approach could help with the identification of patients with HNSCC who may benefit from immunotherapy.

Citing Articles

From Images to Genes: Radiogenomics Based on Artificial Intelligence to Achieve Non-Invasive Precision Medicine in Cancer Patients.

Guo Y, Li T, Gong B, Hu Y, Wang S, Yang L Adv Sci (Weinh). 2024; 12(2):e2408069.

PMID: 39535476 PMC: 11727298. DOI: 10.1002/advs.202408069.


Validation of a Machine Learning Model to Predict Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.

Lee A, Valero C, Yoo S, Vos J, Chowell D, Morris L Cancers (Basel). 2024; 16(1).

PMID: 38201602 PMC: 10778506. DOI: 10.3390/cancers16010175.

References
1.
Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

2.
Foy J, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J . Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors. Data Brief. 2022; 44:108556. PMC: 9467865. DOI: 10.1016/j.dib.2022.108556. View

3.
Sun R, Henry T, Laville A, Carre A, Hamaoui A, Bockel S . Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?. J Immunother Cancer. 2022; 10(7). PMC: 9260846. DOI: 10.1136/jitc-2022-004848. View

4.
Kocak B, Durmaz E, Kaya O, Ates E, Kilickesmez O . Reliability of Single-Slice-Based 2D CT Texture Analysis of Renal Masses: Influence of Intra- and Interobserver Manual Segmentation Variability on Radiomic Feature Reproducibility. AJR Am J Roentgenol. 2019; 213(2):377-383. DOI: 10.2214/AJR.19.21212. View

5.
Tramm T, Di Caterino T, Jylling A, Lelkaitis G, Laenkholm A, Rago P . Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists. Acta Oncol. 2017; 57(1):90-94. DOI: 10.1080/0284186X.2017.1403040. View